<DOC>
	<DOCNO>NCT03047629</DOCNO>
	<brief_summary>This Phase 1/2a study ass safety , tolerability , pharmacokinetics , pharmacodynamics orally-administered medication relieve symptom constipation associate Parkinson 's Disease . Ten patient enrol Phase 1 , study 8-12 week period . Forty patient enrol Phase 2 , study 8-10 week period . All subject receive study drug one observational period study .</brief_summary>
	<brief_title>Evaluation Safety Tolerability ENT-01 Treatment Parkinson 's Disease Related Constipation</brief_title>
	<detailed_description>Phase 1 enroll 10 patient assess safety , tolerability , pharmacokinetics single escalate dos 30-60 day period . The dose-escalation period precede 2-week run period follow 2-week wash-out period . Phase 2 follow safe completion Phase 1 . It enroll 40 patient compose 4 period study : 1 ) 2-week run-in period , 2 ) 3-5 week escalate dose period identify prokinetic dose initial set 10 patient , 3 ) 1-week period randomize dosing ( placebo versus previously identify pro-kinetic dose ) , 4 ) 2-week wash-out period . Pharmacodynamics assess along safety tolerability . Relative outcome compare within patient across group randomize dosing period . Frequency bowel movement non-motor symptom Parkinson 's Disease collect course phase .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Parkinson 's disease diagnosis confirm neurologist specialize movement disorder 2 . Insufficient criterion diagnosis Irritable Bowel Syndrome 3 . Constipation 6 month , unresponsive Milk Magnesia , require least weekly treatment use oral laxative , stool softener , bulk agent , and/or suppository , dissatisfaction current treatment . 4 . Body Mass Index 1840 kg/m2 5 . At least 2 Rome IV functional constipation criterion meet 6 . Loose stool rarely present without use laxatives 7 . Patient willing able sign inform consent comply study procedures 8 . Patients must able read , understand , accurately record data diary guarantee full participation study Females : 9 . Must negative serum urine pregnancy test must lactate 10 . If childbearing age : Must agree use hormonal ( i.e. , oral , implantable , injectable ) either single doublebarrier method birth control throughout study period . A vasectomized partner allow one conjunction another singlebarrier method . 11 . If unable child : Must document case report form ( i.e. , ubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . Postmenopausal status confirm follicle stimulate hormone woman le 60 year age . 1 . Unable unwilling provide inform consent comply study procedures 2 . Diagnosis secondary constipation beyond PD 3 . Structural metabolic disease affect GI system 4 . Functional GI disorder 5 . Unable unwilling withdraw take follow medication 2 week prior doseescalation period throughout study : Laxatives , opiate , sedative , hypnotic , antihistamine , protein pump inhibitor medication may cause constipation 6 . History recent major surgery ( within 60 day screen ) 7 . Any clinically significant abnormality screen laboratory physical examination determine Investigator 8 . Neurological disorder PD 9 . On treatment intrajejunal dopamine 10 . Treatment COMT inhibitor fewer 4 week ( entacapone , tolcapone , Stalevo ) 11 . Unable maintain stable diet regimen 12 . Patients cognitive impairment preclude understand informed consent 13 . Patients place legal guardianship 14 . Acute GI illness within 48 hour baseline period 15 . History major GI surgery ( e.g . previous abdominal surgery , include cholecystectomy ) , except patient uncomplicated appendectomy allow 16 . ALT AST &gt; 1.5 X upper limit normal ( ULN ) screen 17 . Females pregnant breastfeed 18 . History excessive alcohol use substance abuse 19 . Patient caregiver unable administer daily oral dose 20 . Participation investigational clinical study within 6 month prior dose present study 21 . Any reason , opinion Investigator would confound proper interpretation study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>non-motor symptom</keyword>
</DOC>